{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T22:35:31Z","timestamp":1774996531287,"version":"3.50.1"},"reference-count":39,"publisher":"American Diabetes Association","issue":"7","license":[{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K23 DK124654\u00e2\u20ac\u201c01-A1"],"award-info":[{"award-number":["K23 DK124654\u00e2\u20ac\u201c01-A1"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Observational and preclinical data suggest metformin may prevent severe coronavirus disease 2019 (COVID-19) outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>We conducted a systematic review of randomized, placebo-controlled clinical trials of metformin treatment for COVID-19 to determine whether metformin affects clinical or laboratory outcomes in individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and present a structured summary of preclinical data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION<\/jats:title>\n                    <jats:p>Two independent reviewers searched PubMed, Scopus, Cochrane COVID-19 Study Register, and ClinicalTrials.gov on 1 February 2023 with no date restrictions for trials where investigators randomized adults with COVID-19 to metformin versus control and assessed clinical and\/or laboratory outcomes of interest. The Cochrane Risk of Bias 2 tool was used to assess bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA EXTRACTION<\/jats:title>\n                    <jats:p>Two reviewers extracted data pertaining to prespecified outcomes of each interest from each included trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS<\/jats:title>\n                    <jats:p>The synthesis plan was developed a priori and was guided by Synthesis Without Meta-analysis (SWiM) guidelines. Summary tables and narrative synthesis were used (PROSPERO, 2022, CRD42022349896). Three randomized trials met inclusion criteria. In two of the trials investigators found that metformin improved clinical outcomes (prevented need for oxygen and prevented need for acute health care use), and in the third trial a larger portion of adults with diabetes were enrolled but results did show a direction of benefit similar to that of the other trials in the per-protocol group. In the largest trial, subjects were enrolled during the delta and omicron waves and vaccinated individuals were included. The certainty of evidence that metformin prevents health care use due to COVID-19 was moderate per Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria. Many preclinical studies have shown metformin to be effective against SARS-CoV-2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LIMITATIONS<\/jats:title>\n                    <jats:p>Limitations include inclusion of only three trials and heterogeneity between trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Future trials will help define the role of metformin in COVID-19 treatment guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc22-2539","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T15:04:04Z","timestamp":1687273444000},"page":"1432-1442","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":20,"title":["Metformin for Treatment of Acute COVID-19: Systematic Review of Clinical Trial Data Against SARS-CoV-2"],"prefix":"10.2337","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0220-4712","authenticated-orcid":false,"given":"Spencer M.","family":"Erickson","sequence":"first","affiliation":[{"name":"1University of Minnesota Medical School, Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah L.","family":"Fenno","sequence":"additional","affiliation":[{"name":"1University of Minnesota Medical School, Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nir","family":"Barzilai","sequence":"additional","affiliation":[{"name":"2Institute for Aging Research, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Kuchel","sequence":"additional","affiliation":[{"name":"3UConn Center on Aging, University of Connecticut Health Center, Farmington, CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenna M.","family":"Bartley","sequence":"additional","affiliation":[{"name":"3UConn Center on Aging, University of Connecticut Health Center, Farmington, CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie Nicole","family":"Justice","sequence":"additional","affiliation":[{"name":"4Sticht Center for Healthy Aging and Alzheimer\u2019s Prevention, Wake Forest University School of Medicine, Winston-Salem, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John B.","family":"Buse","sequence":"additional","affiliation":[{"name":"5Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5858-2080","authenticated-orcid":false,"given":"Carolyn T.","family":"Bramante","sequence":"additional","affiliation":[{"name":"6Division of General Internal Medicine, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"key":"2023062019034395900_B1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12916-022-02397-y","article-title":"Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis","volume":"20","author":"Zeng","year":"2022","journal-title":"BMC Med"},{"key":"2023062019034395900_B2","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.arcmed.2021.04.006","article-title":"COVID-19 vaccine diplomacy and equitable access to vaccines amid ongoing pandemic","volume":"52","author":"Sharun","year":"2021","journal-title":"Arch Med Res"},{"key":"2023062019034395900_B3","doi-asserted-by":"crossref","first-page":"102792","DOI":"10.1016\/j.jaut.2021.102792","article-title":"Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy","volume":"127","author":"Haque","year":"2022","journal-title":"J Autoimmun"},{"key":"2023062019034395900_B4","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s11357-020-00261-6","article-title":"A geroscience perspective on immune resilience and infectious diseases: a potential case for metformin","volume":"43","author":"Justice","year":"2021","journal-title":"Geroscience"},{"key":"2023062019034395900_B5","doi-asserted-by":"crossref","first-page":"112230","DOI":"10.1016\/j.biopha.2021.112230","article-title":"Metformin to decrease COVID-19 severity and mortality: Molecular mechanisms and therapeutic potential","volume":"144","author":"Kamyshnyi","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"2023062019034395900_B6","doi-asserted-by":"crossref","first-page":"704666","DOI":"10.3389\/fmed.2021.704666","article-title":"Metformin in patients with COVID-19: a systematic review and meta-analysis","volume":"8","author":"Li","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2023062019034395900_B7","doi-asserted-by":"crossref","first-page":"110157","DOI":"10.1016\/j.diabres.2022.110157","article-title":"Metformin is associated with reduced COVID-19 severity in patients with prediabetes","volume":"194","author":"Chan","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"2023062019034395900_B8","doi-asserted-by":"crossref","first-page":"e0271574","DOI":"10.1371\/journal.pone.0271574","article-title":"Diabetes medications and associations with Covid-19 outcomes in the N3C database: a national retrospective cohort study","volume":"17","author":"Bramante","year":"2022","journal-title":"PLoS One"},{"key":"2023062019034395900_B9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11239-022-02631-7","article-title":"Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes","volume":"53","author":"Usman","year":"2022","journal-title":"J Thromb Thrombolysis"},{"key":"2023062019034395900_B10","doi-asserted-by":"crossref","first-page":"155223","DOI":"10.1016\/j.metabol.2022.155223","article-title":"Metformin: is it a drug for all reasons and diseases?","volume":"133","author":"Triggle","year":"2022","journal-title":"Metabolism"},{"key":"2023062019034395900_B11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2020.04.001","article-title":"Benefits of metformin in attenuating the hallmarks of aging","volume":"32","author":"Kulkarni","year":"2020","journal-title":"Cell Metab"},{"key":"2023062019034395900_B12","doi-asserted-by":"crossref","first-page":"8743","DOI":"10.1038\/s41598-021-87707-9","article-title":"The antiviral effect of metformin on zika and dengue virus infection","volume":"11","author":"Farfan-Morales","year":"2021","journal-title":"Sci Rep"},{"key":"2023062019034395900_B13","doi-asserted-by":"crossref","first-page":"101359","DOI":"10.1016\/j.diabet.2022.101359","article-title":"Protection by metformin against severe Covid-19: An in-depth mechanistic analysis","volume":"48","author":"Wiernsperger","year":"2022","journal-title":"Diabetes Metab"},{"key":"2023062019034395900_B14","doi-asserted-by":"crossref","first-page":"587801","DOI":"10.3389\/fendo.2021.587801","article-title":"Metformin and Covid-19: focused review of mechanisms and current literature suggesting benefit","volume":"12","author":"Ibrahim","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2023062019034395900_B15","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/CIRCRESAHA.116.308445","article-title":"Anti-inflammatory effects of metformin irrespective of diabetes status","volume":"119","author":"Cameron","year":"2016","journal-title":"Circ Res"},{"key":"2023062019034395900_B16","doi-asserted-by":"crossref","first-page":"784459","DOI":"10.3389\/fphar.2022.784459","article-title":"Diabetes, metformin and the clinical course of Covid-19: outcomes, mechanisms and suggestions on the therapeutic use of metformin","volume":"13","author":"Bailey","year":"2022","journal-title":"Front Pharmacol"},{"key":"2023062019034395900_B17","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1038\/s41598-022-09639-2","article-title":"Metformin is associated with favorable outcomes in patients with COVID-19 and type 2 diabetes mellitus","volume":"12","author":"Ma","year":"2022","journal-title":"Sci Rep"},{"key":"2023062019034395900_B18","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2023062019034395900_B19","doi-asserted-by":"crossref","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"2023062019034395900_B20","doi-asserted-by":"crossref","unstructured":"Erickson\n              S\n            , BramanteC, FennoS. Metformin for treatment of Covid-19: a systematic review of clinical trial data against SARS-Cov-2. Accessed 30 December 2022. Available from\u00a0https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42022349896","DOI":"10.2337\/figshare.22265911.v1"},{"key":"2023062019034395900_B21","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2023062019034395900_B22","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2023062019034395900_B23","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","volume":"583","author":"Gordon","year":"2020","journal-title":"Nature"},{"key":"2023062019034395900_B24","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/s41418-021-00916-7","article-title":"SARS-CoV-2 non-structural protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1","volume":"29","author":"Sun","year":"2022","journal-title":"Cell Death Differ"},{"key":"2023062019034395900_B25","doi-asserted-by":"crossref","first-page":"199010","DOI":"10.1016\/j.virusres.2022.199010","article-title":"Metformin suppresses SARS-CoV-2 in cell culture","volume":"323","author":"Parthasarathy","year":"2022","journal-title":"Virus Res"},{"key":"2023062019034395900_B26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2201662","article-title":"Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19","volume":"387","author":"Bramante","year":"2022","journal-title":"N Engl J Med"},{"key":"2023062019034395900_B27","first-page":"100142","article-title":"Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial","volume":"6","author":"Reis","year":"2022","journal-title":"Lancet Reg Health Am"},{"key":"2023062019034395900_B28","doi-asserted-by":"crossref","first-page":"113223","DOI":"10.1016\/j.biopha.2022.113223","article-title":"Treatment with metformin glycinate reduces SARS-CoV-2 viral load: an in\u00a0vitro model and randomized, double-blind, phase IIb clinical trial","volume":"152","author":"Ventura-L\u00f3pez","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"2023062019034395900_B29","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMra1510064","article-title":"The primary outcome fails - what next?","volume":"375","author":"Pocock","year":"2016","journal-title":"N Engl J Med"},{"key":"2023062019034395900_B30","unstructured":"U.S. Food and Drug Administration\n          . Pulse Oximeter Accuracy and Limitations: FDA Safety Communication, 2021. Accessed 12 January 2023. Available from https:\/\/www.fda.gov\/medical-devices\/safety-communications\/pulse-oximeter-accuracy-andlimitations-fda-safety-communication"},{"key":"2023062019034395900_B31","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2337\/dc15-0488","article-title":"The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies","volume":"39","author":"Buse","year":"2016","journal-title":"Diabetes Care"},{"key":"2023062019034395900_B32","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2337\/db10-0805","article-title":"OCT1 expression in adipocytes could contribute to increased metformin action in obese subjects","volume":"60","author":"Moreno-Navarrete","year":"2011","journal-title":"Diabetes"},{"key":"2023062019034395900_B33","doi-asserted-by":"crossref","first-page":"1025495","DOI":"10.3389\/fimmu.2022.1025495","article-title":"Targeting T cell (oxidative) metabolism to improve immunity to viral infection in the context of obesity","volume":"13","author":"Greene","year":"2022","journal-title":"Front Immunol"},{"key":"2023062019034395900_B34","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/pathogens11020270","article-title":"Patients with obesity and a history of metformin treatment have lower influenza mortality: a retrospective cohort study","volume":"11","author":"Cummings","year":"2022","journal-title":"Pathogens"},{"key":"2023062019034395900_B35","doi-asserted-by":"crossref","first-page":"e148003","DOI":"10.1172\/jci.insight.148003","article-title":"Ex vivo SARS-CoV-2 infection of human lung reveals heterogeneous host defense and therapeutic responses","volume":"6","author":"Schaller","year":"2021","journal-title":"JCI Insight"},{"key":"2023062019034395900_B36","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.immuni.2021.05.004","article-title":"Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation","volume":"54","author":"Xian","year":"2021","journal-title":"Immunity"},{"key":"2023062019034395900_B37","doi-asserted-by":"crossref","first-page":"733921","DOI":"10.3389\/fimmu.2021.733921","article-title":"Metformin suppresses monocyte immunometabolic activation by SARS-CoV-2 spike protein subunit 1","volume":"12","author":"Cory","year":"2021","journal-title":"Front Immunol"},{"key":"2023062019034395900_B38","article-title":"SARS-CoV-2 infection causes dopaminergic neuron senescence","author":"Chen","journal-title":"Res Sq"},{"key":"2023062019034395900_B39","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s42003-022-03789-9","article-title":"The spike of SARS-CoV-2 promotes metabolic rewiring in hepatocytes","volume":"5","author":"Mercado-G\u00f3mez","year":"2022","journal-title":"Commun Biol"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/46\/7\/1432\/725913\/dc222539.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/46\/7\/1432\/725913\/dc222539.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T15:04:35Z","timestamp":1687273475000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/46\/7\/1432\/151544\/Metformin-for-Treatment-of-Acute-COVID-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":39,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,6,20]]},"published-print":{"date-parts":[[2023,7,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc22-2539","relation":{"has-preprint":[{"id-type":"doi","id":"10.2337\/figshare.22265911","asserted-by":"object"},{"id-type":"doi","id":"10.2337\/figshare.22265911.v1","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.2337\/figshare.22265911","asserted-by":"object"},{"id-type":"doi","id":"10.2337\/figshare.22265911.v1","asserted-by":"object"}]},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,20]]}}}